These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 26109850)
1. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Cicero AF; Colletti A; Borghi C Drug Des Devel Ther; 2015; 9():3073-82. PubMed ID: 26109850 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. Cicero AF; Tartagni E; Ertek S Expert Opin Biol Ther; 2014 Jun; 14(6):863-8. PubMed ID: 24661068 [TBL] [Abstract][Full Text] [Related]
3. Evolocumab: A Review in Hyperlipidemia. Keating GM Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308 [TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Blom DJ; Dent R; Castro RC; Toth PP Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264 [TBL] [Abstract][Full Text] [Related]
5. Evolocumab: Considerations for the Management of Hyperlipidemia. Wiggins BS; Senfield J; Kassahun H; Lira A; Somaratne R Curr Atheroscler Rep; 2018 Mar; 20(4):17. PubMed ID: 29511875 [TBL] [Abstract][Full Text] [Related]
6. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Cicero AF; Tartagni E; Ertek S Expert Opin Drug Saf; 2014 Aug; 13(8):1023-30. PubMed ID: 24961142 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS; Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985 [TBL] [Abstract][Full Text] [Related]
10. Evolocumab for the treatment of hypercholesterolemia. Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM Expert Opin Biol Ther; 2017 Nov; 17(11):1447-1461. PubMed ID: 28812389 [TBL] [Abstract][Full Text] [Related]
14. Evolocumab (AMG 145) for primary hypercholesterolemia. Langslet G; Emery M; Wasserman SM Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308 [TBL] [Abstract][Full Text] [Related]
15. [The new lipid-lowering drugs: focus on monoclonal antibodies]. Borghi C; Cimminiello C G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):14S-21. PubMed ID: 27312019 [TBL] [Abstract][Full Text] [Related]
16. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Page MM; Watts GF Expert Opin Drug Metab Toxicol; 2015; 11(9):1505-15. PubMed ID: 26293511 [TBL] [Abstract][Full Text] [Related]
17. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia. Sible AM; Nawarskas JJ; Anderson JR Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Okere AN; Serra C Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279 [TBL] [Abstract][Full Text] [Related]
19. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
20. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R; JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]